These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 35281061)

  • 1. Improving Cancer Immunotherapy: Exploring and Targeting Metabolism in Hypoxia Microenvironment.
    Wei J; Hu M; Du H
    Front Immunol; 2022; 13():845923. PubMed ID: 35281061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic interventions: A new insight into the cancer immunotherapy.
    Yu T; Dong T; Eyvani H; Fang Y; Wang X; Zhang X; Lu X
    Arch Biochem Biophys; 2021 Jan; 697():108659. PubMed ID: 33144083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of lipid metabolic reprogramming in tumor microenvironment.
    Yang K; Wang X; Song C; He Z; Wang R; Xu Y; Jiang G; Wan Y; Mei J; Mao W
    Theranostics; 2023; 13(6):1774-1808. PubMed ID: 37064872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer.
    Chouaib S; Noman MZ; Kosmatopoulos K; Curran MA
    Oncogene; 2017 Jan; 36(4):439-445. PubMed ID: 27345407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia-driven metabolic heterogeneity and immune evasive behaviour of gastrointestinal cancers: Elements of a recipe for disaster.
    Mishra AK; Singh SK; Dayanandan S; Banerjee S; Chakraborty S; Gopal AB; Samal S; Poirah I; Chakraborty D; Bhattacharyya A
    Cytokine; 2022 Aug; 156():155917. PubMed ID: 35660715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy.
    Wang B; Zhao Q; Zhang Y; Liu Z; Zheng Z; Liu S; Meng L; Xin Y; Jiang X
    J Exp Clin Cancer Res; 2021 Jan; 40(1):24. PubMed ID: 33422072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy.
    Fan C; Zhang S; Gong Z; Li X; Xiang B; Deng H; Zhou M; Li G; Li Y; Xiong W; Zeng Z; Li X
    Sci China Life Sci; 2021 Apr; 64(4):534-547. PubMed ID: 32815067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic reprogramming of the tumor microenvironment to enhance immunotherapy.
    Lim SA
    BMB Rep; 2024 Sep; 57(9):388-399. PubMed ID: 38919017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reprogramming of glutamine metabolism and its impact on immune response in the tumor microenvironment.
    Ma G; Zhang Z; Li P; Zhang Z; Zeng M; Liang Z; Li D; Wang L; Chen Y; Liang Y; Niu H
    Cell Commun Signal; 2022 Jul; 20(1):114. PubMed ID: 35897036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impacts and mechanisms of metabolic reprogramming of tumor microenvironment for immunotherapy in gastric cancer.
    Zhao L; Liu Y; Zhang S; Wei L; Cheng H; Wang J; Wang J
    Cell Death Dis; 2022 Apr; 13(4):378. PubMed ID: 35444235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunity, Hypoxia, and Metabolism-the Ménage à Trois of Cancer: Implications for Immunotherapy.
    Riera-Domingo C; Audigé A; Granja S; Cheng WC; Ho PC; Baltazar F; Stockmann C; Mazzone M
    Physiol Rev; 2020 Jan; 100(1):1-102. PubMed ID: 31414610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Hypoxia: A Key Determinant of Microenvironment Hostility and a Major Checkpoint during the Antitumor Response.
    Francis A; Venkatesh GH; Zaarour RF; Zeinelabdin NA; Nawafleh HH; Prasad P; Buart S; Terry S; Chouaib S
    Crit Rev Immunol; 2018; 38(6):505-524. PubMed ID: 31002604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia-modulatory nanomaterials to relieve tumor hypoxic microenvironment and enhance immunotherapy: Where do we stand?
    Yuan CS; Deng ZW; Qin D; Mu YZ; Chen XG; Liu Y
    Acta Biomater; 2021 Apr; 125():1-28. PubMed ID: 33639310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia as a potential inducer of immune tolerance, tumor plasticity and a driver of tumor mutational burden: Impact on cancer immunotherapy.
    Abou Khouzam R; Janji B; Thiery J; Zaarour RF; Chamseddine AN; Mayr H; Savagner P; Kieda C; Gad S; Buart S; Lehn JM; Limani P; Chouaib S
    Semin Cancer Biol; 2023 Dec; 97():104-123. PubMed ID: 38029865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy.
    Huang L; Xu H; Peng G
    Cell Mol Immunol; 2018 May; 15(5):428-437. PubMed ID: 29553135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moving Immune Therapy Forward Targeting TME.
    Goliwas KF; Deshane JS; Elmets CA; Athar M
    Physiol Rev; 2021 Apr; 101(2):417-425. PubMed ID: 32790578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the metabolic alteration-modulated tumor microenvironment mediated by TP53 mutation and hypoxia.
    Luo K; Qian Z; Jiang Y; Lv D; Zhu K; Shao J; Hu Y; Lv C; Huang Q; Gao Y; Jin S; Shang D
    Comput Biol Med; 2023 Sep; 163():107078. PubMed ID: 37356294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alleviating hypoxia to improve cancer immunotherapy.
    Fan P; Zhang N; Candi E; Agostini M; Piacentini M; ; Shi Y; Huang Y; Melino G
    Oncogene; 2023 Dec; 42(49):3591-3604. PubMed ID: 37884747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic reprogramming due to hypoxia in pancreatic cancer: Implications for tumor formation, immunity, and more.
    Hao X; Ren Y; Feng M; Wang Q; Wang Y
    Biomed Pharmacother; 2021 Sep; 141():111798. PubMed ID: 34120068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Promise of Targeting Hypoxia to Improve Cancer Immunotherapy: Mirage or Reality?
    Janji B; Chouaib S
    Front Immunol; 2022; 13():880810. PubMed ID: 35795658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.